Syros Pharmaceuticals, Inc. (SYRS)
Stock Price:
$10.85 USD
0.48 (4.63%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
495.77M |
| Revenue (ttm) |
3.91M |
| Net Income (ttm) |
-76.20M |
| Shares Out |
45.69M |
| EPS (ttm) |
-1.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$10.85 |
| Previous Close |
$10.37 |
| Change ($) |
0.48 |
| Change (%) |
4.63% |
| Day's Open |
10.30 |
| Day's Range |
10.12 - 10.89 |
| Day's Volume |
196,981 |
| 52-Week Range |
4.26 - 12.75 |
More Stats
| Market Cap |
495.77M |
| Enterprise Value |
419.80M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.69M |
| Float |
38.25M |
| EPS (basic) |
-1.79 |
| EPS (diluted) |
-1.78 |
| FCF / Share |
-1.22 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.19M |
| Short Ratio |
7.28 |
| Short % of Float |
11.92% |
| Beta |
1.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
126.89 |
| PB Ratio |
6.02 |
| Revenue |
3.91M |
| Operating Income |
-78.11M |
| Net Income |
-76.20M |
| Free Cash Flow |
-53.41M |
| Net Cash |
75.97M |
| Net Cash / Share |
1.66 |
| Gross Margin |
50.73% |
| Operating Margin |
-1,999.13% |
| Profit Margin |
-1,950.40% |
| FCF Margin |
-1,367.14% |
| ROA |
-39.08% |
| ROE |
-108.43% |
| ROIC |
-88.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.86*
(18.53% upside)
Low
8.00
Current: $10.85
High
17.00
Target: 12.86
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 1.98 | 2.05 | 1.10 | 0.32 | 0.32 | - |
| Revenue Growth | -3.32% | 86.19% | 247.32% | 0% | - | - |
| Gross Profit | 1.98 | 2.05 | 1.10 | 0.32 | 0.32 | - |
| Operating Income | -77.74 | -64.30 | -54.69 | -47.96 | -29.82 | -13.44 |
| Net Income | -75.44 | -62.28 | -54.01 | -47.74 | -29.82 | -13.43 |
| Shares Outstanding | 40.22 | 32.66 | 25.41 | 12.70 | 1.98 | 1.53 |
| Earnings Per Share | -1.88 | -1.91 | -2.13 | -4.05 | -17.55 | -10.26 |
| Operating Cash Flow | -60.25 | -40.32 | -44.73 | -40.54 | -23.03 | -11.97 |
| Capital Expenditures | -12.53 | -1.38 | -0.82 | -2.32 | -1.18 | -0.20 |
| Free Cash Flow | -72.78 | -41.69 | -45.55 | -42.86 | -24.21 | -12.17 |
| Cash & Equivalents | 91.71 | 100 | 72.24 | 84.08 | 36.39 | 60.46 |
| Total Debt | 25.92 | 0.03 | 0.05 | 0.22 | 0.34 | - |
| Net Cash / Debt | 65.79 | 100 | 72.19 | 83.86 | 36.05 | 60.46 |
| Assets | 150 | 107 | 78.49 | 91.32 | 43.63 | 61.49 |
| Liabilities | 70.79 | 28.18 | 13.16 | 10.72 | 91.60 | 83.27 |
| Book Value | 79.18 | 78.59 | 65.32 | 80.60 | -47.96 | -21.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Syros Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
83 |
| CEO |
Nancy A. Simonian |
Stock Information
| Ticker Symbol |
SYRS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SYRS |
| IPO Date |
June 30, 2016 |
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.